# Oric Pharmaceuticals, Inc.: filings

ORIC · Nasdaq · CIK 1796280 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/oric.md) · [Financials](/companies/oric/financials.md) · [Filings](/companies/oric/filings.md) · [Insiders](/companies/oric/insiders.md)

## Reports and events: 108 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 148, 8-K 65, SC 13G/A 23, 144 21, 10-Q 20, 3 14, SC 13G 14, SCHEDULE 13G/A 12, CORRESP 11, S-8 8, UPLOAD 8, 10-K 6, DEF 14A 6, DEFA14A 6, EFFECT 6, ARS 4, SC 13D/A 4, SCHEDULE 13G 4, 424B5 3, 4/A 3, D 3, S-3 3, 424B4 2, DRS 2, S-1 2, S-1/A 2, S-1MEF 2, S-3ASR 2, 424B3 1, 8-A12B 1, CERT 1, DRS/A 1, DRSLTR 1, POS AM 1, POSASR 1, SC 13D 1, SCHEDULE 13D 1, SCHEDULE 13D/A 1, SC TO-I 1, SC TO-I/A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 08:00 ET | [8-K](/filings/0001193125-26-429465.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-429465 |
| 2026-08-03 | 20:20 ET | [10-Q](/filings/0001193125-26-330631.md) | Quarterly report, period 2026-06-30 | 0001193125-26-330631 |
| 2026-08-03 | 20:10 ET | [8-K](/filings/0001193125-26-330568.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-330568 |
| 2026-07-30 | 20:49 ET | [8-K](/filings/0001193125-26-326309.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-326309 |
| 2026-06-22 | 20:05 ET | [8-K](/filings/0001193125-26-277511.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-277511 |
| 2026-05-04 | 20:20 ET | [10-Q](/filings/0001193125-26-204047.md) | Quarterly report, period 2026-03-31 | 0001193125-26-204047 |
| 2026-05-04 | 20:10 ET | [8-K](/filings/0001193125-26-203993.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-203993 |
| 2026-04-28 | 20:03 ET | [DEF 14A](/filings/0001193125-26-186911.md) | Proxy statement, period 2026-06-18 | 0001193125-26-186911 |
| 2026-03-31 | 20:16 ET | [8-K](/filings/0001193125-26-134618.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-134618 |
| 2026-02-23 | 22:06 ET | [8-K](/filings/0001193125-26-064291.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-064291 |
| 2026-02-23 | 21:15 ET | [10-K](/filings/0001193125-26-064005.md) | Annual report, period 2025-12-31 | 0001193125-26-064005 |
| 2026-02-23 | 21:10 ET | [8-K](/filings/0001193125-26-063974.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-063974 |
| 2025-12-08 | 11:02 ET | [8-K](/filings/0001193125-25-310472.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-310472 |
| 2025-11-13 | 21:25 ET | [8-K](/filings/0001193125-25-280247.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-280247 |
| 2025-11-13 | 21:20 ET | [10-Q](/filings/0001193125-25-280234.md) | Quarterly report, period 2025-09-30 | 0001193125-25-280234 |
| 2025-11-13 | 21:15 ET | [8-K](/filings/0001193125-25-280196.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-280196 |
| 2025-08-14 | 20:05 ET | [SCHEDULE 13D/A](/filings/0000950170-25-108850.md) | Ownership report, active investor, amended | 0000950170-25-108850 |
| 2025-08-12 | 20:20 ET | [10-Q](/filings/0000950170-25-107359.md) | Quarterly report, period 2025-06-30 | 0000950170-25-107359 |
| 2025-08-12 | 20:10 ET | [8-K](/filings/0000950170-25-107313.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 9.01 Financial statements and exhibits | 0000950170-25-107313 |
| 2025-06-13 | 20:05 ET | [8-K](/filings/0001193125-25-140725.md) | 5.07 Shareholder vote results | 0001193125-25-140725 |
| 2025-06-05 | 21:17 ET | [SCHEDULE 13D](/filings/0000950170-25-082520.md) | Ownership report, active investor | 0000950170-25-082520 |
| 2025-05-28 | 20:42 ET | [8-K](/filings/0001193125-25-129531.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-129531 |
| 2025-05-05 | 20:20 ET | [10-Q](/filings/0000950170-25-063564.md) | Quarterly report, period 2025-03-31 | 0000950170-25-063564 |
| 2025-05-05 | 20:10 ET | [8-K](/filings/0000950170-25-063540.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-063540 |
| 2025-04-23 | 20:06 ET | [DEF 14A](/filings/0001193125-25-091359.md) | Proxy statement, period 2025-06-11 | 0001193125-25-091359 |
| 2025-03-14 | 20:02 ET | [8-K](/filings/0001193125-25-054784.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-25-054784 |
| 2025-02-25 | 21:34 ET | [8-K](/filings/0001193125-25-035203.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-035203 |
| 2025-02-18 | 21:20 ET | [10-K](/filings/0000950170-25-022273.md) | Annual report, period 2024-12-31 | 0000950170-25-022273 |
| 2025-02-18 | 21:10 ET | [8-K](/filings/0000950170-25-022219.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-022219 |
| 2025-01-13 | 13:30 ET | [8-K](/filings/0001193125-25-005028.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-005028 |
| 2024-11-12 | 21:20 ET | [10-Q](/filings/0000950170-24-125471.md) | Quarterly report, period 2024-09-30 | 0000950170-24-125471 |
| 2024-11-12 | 21:10 ET | [8-K](/filings/0000950170-24-125386.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125386 |
| 2024-08-12 | 20:20 ET | [10-Q](/filings/0000950170-24-095467.md) | Quarterly report, period 2024-06-30 | 0000950170-24-095467 |
| 2024-08-12 | 20:10 ET | [8-K](/filings/0000950170-24-095419.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-095419 |
| 2024-06-14 | 20:05 ET | [8-K](/filings/0001193125-24-161593.md) | 5.07 Shareholder vote results | 0001193125-24-161593 |
| 2024-05-06 | 20:20 ET | [10-Q](/filings/0000950170-24-053582.md) | Quarterly report, period 2024-03-31 | 0000950170-24-053582 |
| 2024-05-06 | 20:10 ET | [8-K](/filings/0000950170-24-053551.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-053551 |
| 2024-04-24 | 20:06 ET | [DEF 14A](/filings/0001193125-24-110069.md) | Proxy statement, period 2024-06-12 | 0001193125-24-110069 |
| 2024-03-29 | 20:15 ET | [8-K](/filings/0001193125-24-082077.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-082077 |
| 2024-03-11 | 20:20 ET | [10-K](/filings/0000950170-24-029298.md) | Annual report, period 2023-12-31 | 0000950170-24-029298 |
| 2024-03-11 | 20:10 ET | [8-K](/filings/0000950170-24-029239.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-029239 |
| 2024-01-22 | 14:01 ET | [8-K](/filings/0001193125-24-011747.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-011747 |
| 2024-01-09 | 14:00 ET | [8-K](/filings/0001193125-24-004909.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-004909 |
| 2023-12-11 | 21:05 ET | [8-K](/filings/0001193125-23-292551.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-292551 |
| 2023-11-06 | 21:20 ET | [10-Q](/filings/0000950170-23-059415.md) | Quarterly report, period 2023-09-30 | 0000950170-23-059415 |
| 2023-11-06 | 21:10 ET | [8-K](/filings/0000950170-23-059392.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-059392 |
| 2023-10-23 | 20:07 ET | [8-K](/filings/0001193125-23-260795.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-260795 |
| 2023-08-10 | 20:20 ET | [10-Q](/filings/0000950170-23-041362.md) | Quarterly report, period 2023-06-30 | 0000950170-23-041362 |
| 2023-08-10 | 20:11 ET | [8-K](/filings/0000950170-23-041326.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-041326 |
| 2023-06-27 | 10:05 ET | [8-K](/filings/0001193125-23-175501.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-175501 |

Page 1 of 3. [Older](/companies/oric/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.